This promotional podcast has been initiated and funded by Merck, and a Merck product will be discussed. The intended audience is multiple sclerosis healthcare professionals in the UK only. The comments of the speakers in this podcast reflect their own opinions and are not necessarily those of Merck.
Cladribine tablets are indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease as defined by clinical or imaging features.
UK Prescribing Information for cladribine can be found here. Adverse event reporting information can be found at the end of this webpage.
NICE guidance can be found here.
Scottish Medicines Consortium information can be found here.
Listen to experts, Klaus Schmierer, Tarunya Arun, Mavis Ayer, and Joela Mathews explore what the label expansion of cladribine tablets means for clinical practice in multiple sclerosis, from four different professional perspectives.
Moderator:
Sue Saville1
Speakers
Klaus Schmierer2,3
Tarunya Arun4,5
Mavis Ayer6
Joela Mathews7
1. Independent Healthcare Communications Specialist
2. Consultant Neurologist, Queen Mary University of London, UK
3. Consultant Neurologist, Barts Health NHS Trust, London, UK
4. Consultant Neurologist, University Hospitals of Coventry and Warwickshire, UK
5. Consultant Neurologist, Warwick University, Warwick, UK
6. Multiple Sclerosis Clinical Nurse Specialist, University Hospital Southampton NHS Foundation Trust, Southampton, UK
7. Neuropharmacist, Barts Health NHS Trust, London, UK
| Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Merck Serono Limited – Tel: +44(0)20 8818 7373 or by email to: [email protected]. |
UK-MAV-00176
October 2025
